Vaccine Safety International Monitoring

Vaccine safety is an important aspect of mass immunization of the population. Adverse reactions that occur following vaccination result in a decrease in public confidence. The aim of this research was to identify information on the development of adverse events after immunization with vaccines included into the national vaccination calendars of the USA, European Union (EU), Japan, China, South Korea and India. Particular attention was paid to vaccines that are not included in the vaccination calendar, but are presented in the Russian Federation. During monitoring of vaccination against human papillomavirus information in the European Union, Japan and the United States, according the possible connection with development of autoimmune diseases was refuted. Monitoring of adverse events after vaccination with rotavirus vaccine I generation in the USA, EU and India, allowed to establish a link with the development of intestine invagination and limit the use of this medicinal product in favor of vaccine II generation. After starting vaccination against influenza was detected narcolepsy as a complication of this procedure; and when analyzing the complications of meningococcal vaccination Guillain — Barre syndrome was detected. We also analyzed information on various complications associated with vaccination against Japanese viral encephalitis, which was included into the national vaccination calendar of countries in Asia and the Pacifi c region — China, India, Japan, and South Korea. The main complications registered in the PRC after the introduction of Japanese encephalitis vaccine into the national vaccination calendar included: febrile seizures, thrombocytopenic purpura, encephalitis and meningitis. The main safety concerns about vaccines included into the national vaccination calendars of EU countries, the USA and the Asia-Pacific region concern vaccines that have recently appeared on the pharmaceutical market.

1. Avdeeva ZI, Alpatova NA, Bondarev VP, Volkova RA, Lonskaya NI, Lebedinskaya EV, et al. Vaccines with adjuvants. Preclinical studies. BIOpreparaty. Profilaktika, diagnostika, lechenie= BIOpreparations. Prevention, Diagnosis, Treatment.2015;(1):15–20 (In Russ.) https://doi.org/10.30895/2221-996X-2015-1-15-20

2. Astakhova AV, Lepakhin VK. Adverse drug reactions and safety controls. Moscow: Eksmo; 2008 (In Russ.)

3. Medunitsin NV. Vaccinology. Moscow: Triada-X; 2004 (In Russ.)

4. Snegireva II, Zatolochina KE, Darmostukova MA, Alyautdin RN, Romanov BK. Modern approaches to vaccines interchangeability. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2016;(4):3–8 (In Russ.)

5. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health. 1995;85(12):1706–9.

6. Stetler HC, Mullen JR, Brennan JP, Livengood JR, Orenstein WA, Hinman AR. Monitoring system for adverse events following immunization. Vaccine. 1987;5(3):169–74. https://doi.org/10.1016/0264-410X(87)90094-6

7. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunisation: Vaccine Adverse Event Reporting System (VAERS) — United States, 1991–2001. MMWR Surveill Summ. 2003;52(1):1–24.

8. Centers for Disease Control and Prevention (CDC). Postmarketing monitoring of intussusception after RotaTeq vaccination — United States, February 1, 2006 — February 15, 2007. MMWR Morb Mortal Wkly Rep. 2007;56(10):218–22.

9. Haber P, Patel M, Izurieta HS, Baggs J, Gargiullo P, Weintraub E, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics. 2008;121(6):1206–12. https://doi.org/10.1542/peds.2007-3793

10. Kassim P, Eslick GD. Risk of intussusception following rotavirus vaccination: An evidence based meta-analysis of cohort and case-control studies. Vaccine.2017;35(33):4276–86. https://doi.org/10.1016/j.vaccine.2017.05.064

11. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med.2001;344(8):564–72. https://doi.org/10.1056/NEJM200102223440804

12. Murphy TV, Smith PJ, Gargiullo PM, Schwartz B. The first rotavirus vaccine and intussusception: epidemiological studies and policy decisions. J Infect Dis. 2003;187(8):1309–13. https://doi.org/10.1086/374420

13. Koch J, Wiese-Posselt M, Remschmidt C, Wichmann O, Bertelsmann H, Garbe E, et al. Background paper to the recommendation for routine rotavirus vaccination of infants in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(7):957–84. https://doi.org/10.1007/s00103-013-1777-3

14. Kalaiselvan V, Thota P, Kumar V, Rathore MS, Thota A, Singh GN. Risk of intussusception with rotavirus vaccine. Indian J Pediatr. 2017;84(2):97– 100. https://doi.org/10.1007/s12098-016-2230-z

15. Winstone AM, Stellitano L, Verity C, Andrews N, Miller E, Stowe J, Shneerson J. Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 infl uenza vaccine in England. Dev Med Child Neurol. 2014;56(11):1117–23. https://doi.org/10.1111/dmcn.12522

16. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1)pdm09 pandemic and vaccination campaigns. Vaccine. 2013;31(8):1246–54. https://doi.org/10.1016/j.vaccine.2012.12.015

17. Johansen K, Brasseur D, MacDonald N, Nohynek H, Vandeputte J, Wood D, et al. Where are we in our understanding of the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines? Biologicals. 2016;44(4):276–80. https://doi.org/10.1016/j.biologicals.2016.04.007

18. Ito H, Noda K, Hirai K, Ukichi T, Furuya K, Kurosaka D. A case of systemic lupus erythematosus (SLE) following Human papillomavirus (HPV) vaccination. Nihon Rinsho Meneki Gakkai Kaishi. 2016; 39(2):145–9. https://doi.org/10.2177/jsci.39.145

19. Inokuma Y, Sato Y, Masuda S. Adverse event reporting patterns of marketing authorization holders, healthcare professionals and patients in Japan: lessons learnt from the human papilloma virus vaccine. Pharm Med. 2018;32(2):123–129. https://doi.org/10.1007/s40290-018-0230-1

20. Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, Krivitzky A, Lebrun-Frenay C, Clet J, et al. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. J Autoimmun. 2017;79:84–90. https://doi.org/10.1016/j.jaut.2017.01.005

21. Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H, Qureshi AI. Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006–2009. Vaccine. 2011;29(5):886–9. https://doi.org/10.1016/j.vaccine.2010.09.020

22. Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275(4):398–408. https://doi.org/10.1111/joim.12155

23. Centers for Disease Control and Prevention (CDC). Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine — United States, June 2005 — September 2006. MMWR Morb Mortal Wkly Rep. 2006;55(43):1177.

24. Centers for Disease Control and Prevention (CDC). Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine — United States, October 2005 — February 2006. MMWR Morb Mortal Wkly Rep. 2006;55(13):364–6.

25. Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21(12):1350–8. https://doi.org/10.1002/pds.3321

26. Yuan X. China’s vaccine production scare. Lancet. 2018;392(10145):371. https://doi.org/10.1016/S0140-6736(18)31725-2

27. Qian Zhecheng. China panics over substandard vaccine scandal. Sixth Tone. 2018.

28. Ye Y, Wang CS, Ma YT, Lu MX, Zhang XX, Zhang YY, Guo WS. Surveillance of adverse events following immunization in Henan Province, China between 2010–2011. CJCP. 2013;15(6):466–71.

29. Wu W, Wang H, Li K, Pekka Nuorti J, Liu D, Xu D, et al. Recipient vaccine-associated paralytic poliomyelitis in China, 2010–2015. Vaccine. 2018;36(9):1209–13. https://doi.org/10.1016/j.vaccine.2018.01.019

30. Wu W, Liu D, Li K, Nuorti JP, Nohynek HM, Xu D, et al. Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008–2013. Vaccine. 2017;35(29):3666–71. https://doi.org/10.1016/j.vaccine.2017.05.021

31. Heffelfinger JD, Li X, Batmunkh N, Grabovac V, Diorditsa S, Liyanage JB, et al. Japanese encephalitis: surveillance and immunization in Asia and the Western Pacific, 2016. Weekly Epidemiological Record. 2017;92(23):323–31.

32. Boo Young Kim, Dong Hyun Kim, Hun Jae Lee, Soo Kyung Jung, Xiao Shan Li, Un Yeong Go, et al. Investigation on the frequency and severity of common adverse reactions of Japanese encephalitis vaccines. Korean J Pediatr Infect Dis. 2009;16(2):183–90. https://doi.org/10.14776/kjpid.2009.16.2.183

33. Muta H, Nagai T, Ito Y, Ihara T, Nakayama T. Effect of age on the incidence of aseptic meningitis following immunization with monovalent mumps vaccine. Vaccine. 2015;33(45):6049–53. https://doi.org/10.1016/j.vaccine.2015.09.068